Novartis dissolves agreement to market Pear Therapeutics ’ prescription digital therapeutics for substance/ opioid abuse

_______________ As Sandoz returns marketing rights for digital therapeutics to Pear, what does it mean for co-promote arrangements? (MM&M): “Sandoz, the generics division of Novartis, is altering commercial course, returning marketing duties for two prescription digital therapeutics (DTx) back to Pear Therapeutics. The move, which some had anticipated, comes 18 months after the two signed a co-promotion deal. Since the Sandoz/Pear pact was widely seen as a litmus test of sorts for pharma’s role in helping distribute this nascent technology, the commercial break-up raises questions about the viability of such partnerships going forward. It also highlights the parties’ sometimes conflicting priorities: pharma’s concern about its core business versus digital therapeutics firms’ worries about funding and investment… Despite the Sandoz/Pear news, he and others foresee such collaborations continuing. DTx still represents a “huge opportunity” for pharma, wrote Alessio Brunello, senior pharma analyst with GlobalData, in a note Thursday. DTx, he said, should see continued partnership activity in R&D and therapeutics, due in part to pressure on health systems from the aging population and increasing costs and in part to the potential of improved adherence. DTx can be prescribed as monotherapy or together with other therapies to prevent, manage or treat diseases across diverse indications, particularly chronic diseases and neurological disorders. Pear’s reSET p...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Cognitive Neuroscience Health & Wellness Professional Development Technology adherence aging-population digital therapeutics DTx FDA marketing Novartis Pear Therapeutics pharma reSET Sandoz Source Type: blogs